The c-Abl inhibitor, nilotinib, protects dopaminergic neurons in a preclinical animal model of Parkinson's disease

Scientific Reports

Volumn 4, Issue , 2014, Pages

  Karuppagounder, Senthilkumar S ^a,b   Brahmachari, Saurav ^a,b   Lee, Yunjong ^a,b   Dawson, Valina L ^a,b   Dawson, Ted M ^a,b   Ko, Han Seok ^a,c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ADRIENNE HELIS MALVIN MEDICAL RESEARCH FOUNDATION   (United States)

^c Diana Helis Henry Medical Research Foundation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 4 METHYL N (3 (4 METHYLIMIDAZOL 1 YL) 5 (TRIFLUOROMETHYL)PHENYL) 3 ((4 PYRIDIN 3 YLPYRIMIDIN 2 YL)AMINO)BENZAMIDE; 4-METHYL-N-(3-(4-METHYLIMIDAZOL-1-YL)-5-(TRIFLUOROMETHYL)PHENYL)-3-((4-PYRIDIN-3-YLPYRIMIDIN-2-YL)AMINO)BENZAMIDE; ABELSON KINASE; NEUROPROTECTIVE AGENT; PARKIN; PYRIMIDINE DERIVATIVE; UBIQUITIN PROTEIN LIGASE;

ANIMAL; ANIMAL BEHAVIOR; ARTICLE; BLOOD BRAIN BARRIER; BRAIN; DISEASE MODEL; DOPAMINERGIC NERVE CELL; DRUG ANTAGONISM; DRUG EFFECT; ENZYME ACTIVATION; MALE; METABOLISM; MOUSE; PARKINSON DISEASE; PATHOLOGY; PHOSPHORYLATION;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; BEHAVIOR, ANIMAL; BLOOD-BRAIN BARRIER; BRAIN; DISEASE MODELS, ANIMAL; DOPAMINERGIC NEURONS; ENZYME ACTIVATION; MALE; MICE; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-ABL; PYRIMIDINES; UBIQUITIN-PROTEIN LIGASES;

EID: 84899892500     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep04874     Document Type: Article

References (27)

1. Savitt, J. M., Dawson, V. L. & Dawson, T. M. Diagnosis and treatment of Parkinson disease: molecules to medicine. J Clin Invest 116, 1744-1754 (2006).
2. Poewe, W., Mahlknecht, P. & Jankovic, J. Emerging therapies for Parkinson's disease. Curr Opin Neurol 25, 448-459 (2012).
3. Jankovic, J. & Poewe, W. Therapies in Parkinson's disease. Curr Opin Neurol 25, 433-447 (2012).
4. Dawson, T. M. & Dawson, V. L. Molecular pathways of neurodegeneration in Parkinson's disease. Science 302, 819-822 (2003).
5. Zhang, Y., Dawson, V. L. & Dawson, T. M. Oxidative stress and genetics in the pathogenesis of Parkinson's disease. Neurobiol Dis 7, 240-250 (2000).
6. Li, B. c-Abl in oxidative stress, aging and cancer. Cell Cycle 4, 246-248 (2005).
7. Schlatterer, S. D., Acker, C. M. & Davies, P. c-Abl in neurodegenerative disease. J Mol Neurosci 45, 445-452 (2011).
8. Alvarez, A. R., Sandoval, P. C., Leal, N. R., Castro, P.U. & Kosik, K. S. Activation of the neuronal c-Abl tyrosine kinase by amyloid-beta-peptide and reactive oxygen species. Neurobiol Dis 17, 326-336 (2004).
9. Imam, S. Z. et al. Novel regulation of parkin function through c-Abl-mediated tyrosine phosphorylation: implications for Parkinson's disease. J Neurosci 31, 157-163 (2011).
10. Ko, H. S. et al. Phosphorylation by the c-Abl protein tyrosine kinase inhibits parkin's ubiquitination and protective function. Proc Natl Acad Sci U S A 107, 16691-16696 (2010).
11. Schlatterer, S. D., Tremblay, M. A., Acker, C. M. & Davies, P. Neuronal c-Abl overexpression leads to neuronal loss and neuroinflammation in the mouse forebrain. J Alzheimers Dis 25, 119-133 (2011).
12. Hebron, M. L., Lonskaya, I. & Moussa, C. E. Nilotinib reverses loss of dopamine neurons and improves motor behavior via autophagic degradation of alphasynuclein in Parkinson's disease models. Hum Mol Genet 22, 3315-3328 (2013).
13. Imam, S. Z. et al. Neuroprotective efficacy of a new brain-penetrating C-Abl inhibitor in a murine Parkinson's disease model. PLoS One 8, e65129 (2013).
14. Mahul-Mellier, A. L. et al. c-Abl phosphorylates alpha-syn and regulates its degradation, implication for alpha-syn clearance and contribution to the pathogenesis of Parkinson's Disease. Hum Mol Genet, (2014).
15. Shin, J. H. et al. PARIS (ZNF746) repression of PGC-1alpha contributes to neurodegeneration in Parkinson's disease. Cell 144, 689-702 (2011).
16. Lee, Y. et al. Parthanatos mediates AIMP2-activated age-dependent dopaminergic neuronal loss. Nat Neurosci 16, 1392-1400 (2013).
17. Dawson, T. M. & Dawson, V. L. Parkin Plays a Role in Sporadic Parkinson's Disease. Neurodegener Dis, (2013).
18. Soverini, S., Martinelli, G., Rosti, G., Iacobucci, I. & Baccarani, M. Advances in treatment of chronic myeloid leukemia with tyrosine kinase inhibitors: the evolving role of Bcr-Abl mutations and mutational analysis. Pharmacogenomics 13, 1271-1284 (2012).
19. Javitch, J. A. & Snyder, S. H. Uptake of MPP(+) by dopamine neurons explains selectivity of parkinsonism-inducing neurotoxin, MPTP. Eur J Pharmacol 106, 455-456 (1984).
20. Steegmann, J. L., Cervantes, F., le Coutre, P., Porkka, K. & Saglio, G. Off-target effects of BCR-ABL1 inhibitors and their potential long-term implications in patients with chronic myeloid leukemia. Leuk Lymphoma 53, 2351-2361 (2012).
21. Thomas, B. et al. Resistance to MPTP-neurotoxicity in alpha-synuclein knockout mice is complemented by human alpha-synuclein and associated with increased beta-synuclein and Akt activation. PLoS One 6, e16706 (2011).
22. Davies, A. et al. Simultaneous determination of nilotinib, imatinib and its main metabolite (CGP-74588) in human plasma by ultra-violet high performance liquid chromatography. Leuk Res 34, 702-707 (2010).
23. Karl, T., Pabst, R. & von Horsten, S. Behavioral phenotyping of mice in pharmacological and toxicological research. Exp Toxicol Pathol 55, 69-83 (2003).
24. Dauer, W. et al. Resistance of alpha -synuclein null mice to the parkinsonian neurotoxin MPTP. Proc Natl Acad Sci U S A 99, 14524-14529 (2002).
25. Hunot, S. et al. JNK-mediated induction of cyclooxygenase 2 is required for neurodegeneration in amouse model of Parkinson's disease. Proc Natl Acad Sci U S A 101, 665-670 (2004).
26. Luk, K. C. et al. Pathological alpha-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science 338, 949-953 (2012).
27. Lane, E. L., Winkler, C., Brundin, P. & Cenci, M. A. The impact of graft size on the development of dyskinesia following intrastriatal grafting of embryonic dopamine neurons in the rat. Neurobiol Dis 22, 334-345 (2006).